OCT. 19, 2017 - "Eventful Q3 17 paving the way for the future"
DECEMBER 12 2017 As the Formulary List of Covered Drugs for 2018 has been announced in the US, Orexo today announces specific information about the improved market access position for Zubsolv® in 2018, earlier communicated in the Q317 report. This progress can mainly be explained by Zubsolv´s preferred position at CVS Caremark and by exclusive contracts with Humana and Envision.
Entering 2018, Zubsolv US will have stronger market access position than ever. Listen to an interview where Robert DeLuca, President of Orexo US Inc, comments on the latest developments for Zubsolv and the accelerating opioid crisis.
NOVEMBER 20 2017 The European Medicines Agency has granted a marketing authorization for Zubsolv in Europe. The approval is an important step in Orexo´s goal to reach out with Zubsolv outside the US. Zubsolv will be an important new option for all those suffering from opioid dependence in Europe.
Entering 2018, our key product in the US will have stronger market access position than ever. Listen to an intervie… https://t.co/nEe8gCCjeF
On Dec. 5th it was announced that the Netflix Documentary Heroin(e) is on the short list for an Oscar. A new film a… https://t.co/je8XFvOfci